AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
Jersey Desk/10303027

LOS ANGELES - JerseyDesk -- Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.

Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).

Launched New AI-Based Neurotoxin Countermeasure Initiative to Assist in Matters of National Security.

Key U.S. Patent to Strengthen AI-Driven Drug Discovery & Diagnostics Platform.

Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets.

Obtained Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology.

Augusta AI-Powered Precision Neurology Platform Integrates Multiomics, Contingent AI, Phenoclustering and CRISPR Screens to Speed Drug Discovery.

Renovaro, Inc. (N A S D A Q: RENB) is building category-defining AI-driven platforms for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.

RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.

RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Launch of AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

On June 30^th RENB unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into the RENB Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector.

The RENB platform is anchored by advanced data preprocessing coupled with in vivo toxicity testing, creating a robust, end-to-end discovery pipeline bolstered by their recently announced patent, "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions". This IP milestone expands the RENB foundational portfolio, further protecting its machine learning infrastructure for multi-modal biomedical data integration and predictive analytics-core to its scalable drug discovery and diagnostics business.

More on Jersey Desk

• 31 Changemakers, Two Coasts, One Message: 'Today is the Day. LIVE IT!' Gains National Acclaim
• FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
• $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
• CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
• Seth Jones Named Caldwell University Head Volleyball Coach

Value Drivers:

Strengthened IP Portfolio: New patent adds to RENB protected methods for real-time, reproducible analytics across distributed computing environments.

Defense Market Entry: The RENB AI-zebrafish platform enables high-throughput, physiologically relevant screening for CNS-active neurotoxins.

Commercial Expansion: The platform is highly adaptable to pharma applications, rare diseases, and clinical trial acceleration.

Differentiated AI Platform: Combines proprietary model optimization, advanced feature selection, and biological automation.

New Revenue Opportunities: Supports RENB partnerships, licensing, and government grants/contracts in both biomedical and national security domains.

The AI-based RENB platform which uses an inexpensive zebrafish-based model for validation of neurotoxicity predictions, delivers rapid, automated screening of over 1,000 compounds per week, significantly outpacing traditional animal models. It captures behavioural, cardiovascular, and muscular responses to neuroactive chemicals, enabling ML-driven compound triage and mechanism of action prediction. This capability is vital for both commercial CNS drug discovery and defense applications involving neurotoxic exposure.

Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

On June 3^rd RENB announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions" (Application No. 18/058,752).

This patent strengthens the RENB AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling.

The new RENB patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies.

Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

On May 22^nd RENB announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (N A S D A Q: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025.

More on Jersey Desk

• PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
• Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
• From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
• Cold. Clean. Anywhere. Meet FrostSkin
• How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment

RENB alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions by conducting a public offering of $545,000 in securities on February 19, 2025—despite contractual restrictions—and later attempting to terminate the agreement unilaterally on April 3, 2025, without engaging meaningfully in the negotiation of a definitive merger agreement.

The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches. The case is pending in the Delaware Court of Chancery under Case No. 2025-0509.

Launch of Augusta AI-Powered Precision Neurology Platform

On May 14^th RENB announced it had launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged. Built on the RENB Renovaro Cube and Elion platforms and recently validated through work in Parkinson's Disease and epilepsy, the platform combines multimodal data analytics with proprietary in silico screening to identify biomarkers and therapeutics in a fraction of the time of conventional methods.

Unlike black-box approaches, the RENB Augusta platform emphasizes interpretability, clinical alignment, and rigorous benchmarking. Augusta's modular infrastructure enables plug-and-play model evaluation, including for large language models (LLMs) conditioned using proprietary knowledge graphs. This supports continuous innovation while maintaining clinical and experimental robustness.

The efficacy of this approach has already been demonstrated in Parkinson's Disease, where phenoclustering identified novel and highly predictable patient subgroups with unique clinical characteristics and biomarkers, and in epilepsy, where novel lead compounds were identified specifically addressing patient populations with rare genetic mutations.

With a strong foundation in Parkinson's disease and epilepsy, RENB plans to expand its precision neurology efforts into additional neurological disorders. Strategic partnerships with academic medical centres and life sciences companies are currently being discussed.

For more information on $RENB visit: http://www.renovarobio.com and https://share.google/S5qMjXPXlFrIGdrJI

Media Contact
Company Name: Renovaro, Inc. (N A S D A Q: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and  https://share.google/S5qMjXPXlFrIGdrJI
Email: ir@renovarobio.com
Phone:  732-780-5036
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website